Shots:

• The P-III (U-EXCEL) induction study to evaluate upadacitinib (45mg) in adults with mod. to sev. CD who had inadequately responded or intolerant to one or more conventional & biological therapies
• The trial met its 1EPs & 2EPs i.e., patients achieved clinical remission @12wks. (49% vs 29%), clinical remission (51% vs 22%), endoscopic response (46% vs 13%), steroid-free clinical remission, symptom improvement & the safety profile was consistent with the safety profile observed in previous studies with no new safety risks, SAEs (6.9% vs 6.8%)
• RINVOQ (15/30mg) is a selective & reversible JAK inhibitor & is approved in the US & EU for AD while 15 mg is also approved in the US & EU for RA

 Ref: PR Newswire | Image: AbbVie